Brain Cancer Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 106 studies associated with Brain Cancer.
Here is a small sampling of Brain Cancer studies by title:
- Preparation of a nanoemulsion containing active ingredients of cannabis extract and its application for glioblastoma: in vitro and in vivo studies
- Arachidonoylethanolamide promotes cellular senescence in a human glioblastoma cell line
- Characterization of the Antitumor Potential of Extracts of Cannabis sativa Strains with High CBD Content in Human Neuroblastoma
- Therapeutic and Supportive Effects of Cannabinoids in Patients with Brain Tumors (CBD Oil and Cannabis)
- Borneol and Tetrandrine Modulate the Blood-Brain Barrier and Blood-Tumor Barrier to Improve the Therapeutic Efficacy of 5-Fluorouracil in Brain Metastasis
Components of the Brain Cancer Research Dashboard
- Dosing information available for Brain Cancer
- Chemotype guidance for treating Brain Cancer with cannabis
- Synopsis of cannabis research for Brain Cancer
- Individual study details for Brain Cancer
Ready to become a subscriber? Go to our PRICING page.
Brain Cancer Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 106 studies associated with Brain Cancer.
Here is a small sampling of Brain Cancer studies by title:
- Preparation of a nanoemulsion containing active ingredients of cannabis extract and its application for glioblastoma: in vitro and in vivo studies
- Arachidonoylethanolamide promotes cellular senescence in a human glioblastoma cell line
- Characterization of the Antitumor Potential of Extracts of Cannabis sativa Strains with High CBD Content in Human Neuroblastoma
- Therapeutic and Supportive Effects of Cannabinoids in Patients with Brain Tumors (CBD Oil and Cannabis)
- Borneol and Tetrandrine Modulate the Blood-Brain Barrier and Blood-Tumor Barrier to Improve the Therapeutic Efficacy of 5-Fluorouracil in Brain Metastasis
Components of the Brain Cancer Research Dashboard
- Dosing information available for Brain Cancer
- Chemotype guidance for treating Brain Cancer with cannabis
- Synopsis of cannabis research for Brain Cancer
- Individual study details for Brain Cancer
Ready to become a subscriber? Go to our PRICING page.
Select New Condition
Overview - Brain Cancer
Description of Brain Cancer
The location, aggressiveness, and size of cancerous brain tumors largely determine survivability and the signs and symptoms likely to develop. As tumors grow, cranial space-occupying symptoms arise, and functional impairment increases. However, a few cases may be asymptomatic and require observation only. In many cases, the whole body, as well as the mind, may be impacted.
Generally speaking, the lower the tumor is in the brain structure, the poorer the survival outcome. This is because the brain's lower portions control the most vital functions, such as breathing and heart rate. Glioblastoma multiforme (GBM) is the most common adult primary brain tumor and has an inferior prognosis. It accounts for 45% of primary brain and CNS tumors. GBM carries a median survival of just 15 months, with a 5.5% survival rate beyond five years. The mean diagnosis age is 62 years, while the lower grade form has a mean age of 45.
Children have a generally better prognosis with brain cancer. In children, the most common brain tumors are medulloblastoma and ependymoma. Other favorable prognostic factors include early detection, young age, and focal partial seizure semiology. Unfortunately, there are no significant or determined risk factors for brain cancer other than genetics.
Disease Classification
Condition: Cancer - BrainDisease Family: Cancer
Organ System: Nervous System
ICD-10 Chapter: Neoplasms
ICD-10 Code: C71
Brain Cancer Symptoms:
Changes in cognition, headache, visual, hearing, or sensory impairments, confusion, changes in affect, seizure activity, nausea, vomiting, nosebleeds, altered mental status, focal neurological deficits, papilledema, hydrocephalus, cerebellar dysfunction (ataxia)Also known as:
Malignant neoplasm of the brain, glioblastoma multiforme (GBM), pituitary carcinoma, craniopharyngioma, pineal region tumors, medulloblastoma, choroid plexus tumor, acoustic neuroma (vestibular schwannoma)Drug Interactions
THC Interaction with Pharmaceutical Drugs
- Tetrahydrocannabinol (THC) can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol.
- THC is metabolized by an inhibitor of several enzymatic liver pathways referred to as cytochrome P450 (aka CYP450). There are more than 50 enzymes belonging to this enzyme family, several of which are responsible for the breakdown of common drugs such as antidepressants (e.g., amitriptyline, doxepin, fluvoxamine), antipsychotics (haloperidol, clozapine, Stelazine), beta-blockers (e.g., propranolol), bronchodilators (e.g., theophylline), or blood thinners (e.g., warfarin). Thus, patients taking these medication classes may find that THC increases the concentration and effects of these drugs and the impact duration.
- Clinical observation (not yet confirmed by clinical trials) suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.
If you are interested in the interaction potential of specific pharmaceuticals with THC, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
CBD Interaction with Pharmaceutical Drugs
- Cannabidiol (CBD) may alter the action of metabolic enzymes (specific drug-transport mechanisms) and alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects.
- Groups of drugs affected include anti-epileptics, psychiatric drugs, and drugs affecting metabolic enzymes.
- Clinical observations (not yet confirmed by clinical trials) suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD.
If you are interested in the interaction potential of specific pharmaceuticals with CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
THC/CBD Interaction with Pharmaceutical Drugs
In general, when using cannabinoid-based therapeutics that contain both THC and CBD consider the ratio between them and weigh the relevant information displayed in the individual THC and CBD Drug Interaction windows accordingly.
If you are interested in the interaction potential of specific pharmaceuticals with both primary cannabinoids and THC/CBD, consider visiting these free drug interaction checkers: Drugs.com or DrugBank Online.
Concerns about Cannabis and Cancer-related Immunotherapies:
Some recent clinical observational studies have suggested that the co-administration of cannabinoid-based therapeutics and immunotherapy or immune checkpoint inhibitors in the treatment of certain types of cancer has been associated with worse overall survival rates (T. Taha et al., 2019; A. Biedny et al., 2020; G. Bar-Sela et al., 2020).
However, other studies have suggested that the co-commitment use of immune checkpoint inhibitors and cannabis-induced no such deleterious effects. More specifically, one trial was conducted on animals resulting in data suggesting that cannabis did not negatively affect the properties of immune checkpoint inhibitors (B. Waissengrin et al., 2023). The same authors compared the previous study results with findings from a cohort of 201 patients with metastatic non-small cell lung cancer who received treatment with monotherapy pembrolizumab as a first-line treatment and adjunct cannabis to treat mainly pain and loss of appetite. Their time to tumor progression was 6.1 versus 5.6 months, and overall survival differed between 54.9 versus 23.6 months in cannabis-naïve patients and cannabis-using patients, respectively. However, while numerically different, the authors write that these differences were not statistically significant, leading them to suggest that “These data provide reassurance regarding the absence of a deleterious effect of cannabis in this clinical setting.”
Dosing Considerations
THC Dosage Considerations
- THC micro dose: 0.1 mg to 0.4 mg
- THC low dose: 0.5 mg to 5 mg
- THC medium dose: 6 mg to 20 mg
- THC high dose: 21 mg to 50+ mg
CBD Dosage Considerations
- CBD low dose: 0.4 mg to 19 mg
- CBD medium dose: 20 mg to 99 mg
- CBD high dose: 100 mg to 800+ mg (upper limits tested ~1,500mg)
Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You
should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a
medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.
